Christian Michael Glibert Buys 240,000 Shares of Nanovibronix (NASDAQ:FEED) Stock

Nanovibronix, Inc. (NASDAQ:FEED) major shareholder Christian Michael Glibert acquired 240,000 shares of Nanovibronix stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average cost of $2.67 per share, with a total value of $640,800.00. Following the completion of the purchase, the insider owned 240,000 shares in the company, valued at approximately $640,800. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Nanovibronix Stock Performance

NASDAQ:FEED opened at $2.84 on Friday. The stock has a market cap of $3.09 million, a price-to-earnings ratio of -0.07 and a beta of 2.21. Nanovibronix, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $162.50.

Analysts Set New Price Targets

Separately, Weiss Ratings assumed coverage on shares of Nanovibronix in a research report on Tuesday, January 27th. They issued a “sell (e+)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.